Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]
, 2017 Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha +161 more
core +2 more sources
Intramural great vessel lymphoma presenting as thrombus in an aortic aneurysm
Human Pathology: Case Reports, 2019 Intravascular large B-cell lymphoma (IVLBCL) is a subtype of extranodal B-cell lymphoma with growth limited to the lumina of small vessels. Intramural great vessel lymphoma (IMGVL), on the contrary, is extremely rare and there have been only two reported
Sameera Rashid +5 more
doaj +1 more source
IJU Case Reports, 2022 Introduction Intravascular large B‐cell lymphoma is a rare and aggressive type of extranodal large B‐cell lymphoma. Although intravascular large B‐cell lymphoma can invade various organs, renal involvement has been rarely reported. Synchronous occurrence
Michio Noda +5 more
doaj +1 more source
Advances in Hematology, 2012 Aggressive B-cell lymphomas (ABLs) are a group of B-cell malignancies, that is, a relatively common form of cancer across the world. This issue on aggressive B-cell lymphomas compiles 12 exciting manuscripts, most of which are very meticulously performed reviews of the available current literature.
Naresh KN +3 more
openaire +4 more sources
Origin and pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma as revealed by global gene expression analysis [PDF]
, 2008 The pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) and its relationship to other lymphomas are largely unknown. This is partly because of the technical challenge of analyzing its rare neoplastic lymphocytic and histiocytic (L&H ...
Brune, Verena +12 more
core +1 more source
A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]
, 2019 The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis +7 more
core +2 more sources
Endoscopic and Histopathological Characteristics of Gastrointestinal Lymphoma: A Multicentric Study
Diagnostics, 2023 Background: Extranodal non-Hodgkin lymphoma (NHL) is more prevalent in the gastrointestinal (GI) tract than in other sites. This study aimed to determine the endoscopic characteristics of primary gastrointestinal non-Hodgkin lymphomas.
Quang Trung Tran +7 more
doaj +1 more source
Diagnosis of anaplastic large-cell lymphoma in a dog using CD30 immunohistochemistry [PDF]
, 2018 Anaplastic large-cell lymphoma or null-cell lymphoma is a clinical entity reported in people, classified according to the unique appearance of large pleomorphic cells that express CD30.
Garden, O A +7 more
core +2 more sources
Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]
, 2016 B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke +2 more
core +1 more source
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. [PDF]
, 2018 Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of ...
Aliberti S +24 more
core +1 more source